Sarepta Therapeutics Inc (SRPT)
Return on total capital
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 279,165 | -498,088 | -636,715 | -355,423 | -493,118 |
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 1,527,740 | 859,337 | 384,950 | 928,009 | 761,759 |
| Return on total capital | 18.27% | -57.96% | -165.40% | -38.30% | -64.73% |
December 31, 2024 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $279,165K ÷ ($—K + $1,527,740K)
= 18.27%
Sarepta Therapeutics Inc's return on total capital fluctuated significantly over the analyzed period. As of December 31, 2020, the company recorded a negative return on total capital of -64.73%, indicating inefficiency in generating returns from its total capital base. However, there was a slight improvement by December 31, 2021, with a negative return of -38.30%. The performance worsened in 2022, with a significant decline to -165.40%, suggesting a concerning use of capital during that period.
By December 31, 2023, there was a partial recovery as the return on total capital improved to -57.96%, although still negative. The most notable improvement was observed by December 31, 2024, when Sarepta Therapeutics Inc achieved a positive return on total capital of 18.27%, indicating better utilization of its total capital to generate returns for its stakeholders.
Overall, the data indicates that Sarepta Therapeutics Inc experienced a mixed performance in terms of return on total capital over the analyzed period, with significant fluctuations reflecting varying levels of capital efficiency and effectiveness in generating returns. Further analysis and monitoring of the company's capital management strategies would be essential to assess its long-term financial sustainability and value creation for investors.
Peer comparison
Dec 31, 2024